•                                 
    Extbase Variable Dump
    'distribution:BiomSpeaker.html' (29 chars)
  •                                     
    Extbase Variable Dump
    'fileadmin/Webdata/Uploads/Veranstaltungen/2025/BayOConnect_2025/Speaker/Ried
     linger_300x300.jpg
    ' (94 chars)
  •                                     
    Extbase Variable Dump
    'Julia Riedlinger' (16 chars)
  •                                     
    Extbase Variable Dump
    'Head of Core Lab Development, Roche Diagnostics Solutions & Center Manager R
     &D Penzberg
    ' (87 chars)
  •                                     
    Extbase Variable Dump
    'Dr. Julia Riedlinger leads RDS R&D Core Lab, overseeing product development
     and on-market care for Clinical Chemistry, Immunochemistry, Coagulation, and
      Mass Spectrometry portfolios. She holds a Pharmacy Degree and a PhD in "Non
     -viral gene delivery", both from LMU Munich.<br> Julia joined Roche in 2006
     as a Management Start-Up Trainee in Research and Early Development of Diagno
     stics. She led biomarker identification programs, established a biobank for
     biomarker discovery and validation across all major disease areas, and was r
     esponsible for teams focusing on biobanking as well as on external research
     collaborations.<br> In 2017, she moved to the Lifecycle Team as a project le
     ad for reagent development Elecsys, successfully driving projects from start
      to worldwide registration and launch. In addition she took on the role of t
     he IVDR program lead, initially for one business area, later for the entire
     Roche Diagnostics portfolio. In 2021, she returned to R&D as Head of Dia Sta
     ndards and Interoperability, shaping processes, internal services, digitaliz
     ation and interoperability across Dia R&D.<br> Since July 2024, Julia Riedli
     nger has been leading the R&D for Core Lab, managing over 1000 employees acr
     oss Germany, Switzerland, Spain and China. She has a very broad experience i
     n end-to-end product development and a strong focus on organizational transf
     ormation.
    ' (1377 chars)